ATC Group: D11AH08 Abrocitinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D11AH08 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D11 Other dermatological preparations
3 D11A Other dermatological preparations
4 D11AH Agents for dermatitis, excluding corticosteroids
5 D11AH08

Active ingredients in D11AH08

Active Ingredient Description
Abrocitinib

Abrocitinib is a Janus kinase (JAK)1 inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of haematopoiesis and immune cell function. JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Inhibition of JAK1 modulates the signalling pathways by preventing the phosphorylation and activation of STATs.

Related product monographs

Title Information Source Document Type  
CIBINQO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Croatia (HR)

Estonia (EE)

Finland (FI)

Ireland (IE)

Israel (IL)

Japan (JP)

Poland (PL)

Romania (RO)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.